Ergoteles’s vTv Therapeutics VTVT Stock Holding History

Ergoteles’s Portfolio VTVT Stock Details VTVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,355	Closed	-$124K	–	1713
2021 Q2	$124K	Buy	+1,355	New	+$137K	﹤0.01%	1369

Other funds holding VTVT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

WAG

Winthrop Advisory Group Boston, Massachusetts $1.48B AUM 22.62% 1-Year Est. Return

CIM

CIM Investment Management Pittsburgh, Pennsylvania $375M AUM 32.03% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $29.1B AUM 22.79% 1-Year Est. Return

Ergoteles's VTVT Position: Q3 2021 in Review

Ergoteles sold out of vTv Therapeutics (VTVT) in Q3 2021, closing a stake of 1,355 shares — an estimated $124K sold.

Ergoteles first reported a position in VTVT in Q2 2021 and held it in 1 quarter. The position peaked at $124K in Q2 2021. 31 funds tracked by Wall St. Rank hold VTVT as of Q3 2021.

Ergoteles reported no remaining vTv Therapeutics position as of Q3 2021 after selling out during the quarter.
Ergoteles sold 1,355 vTv Therapeutics shares in Q3 2021, an estimated $124K.
Ergoteles first reported a position in vTv Therapeutics in Q2 2021 and held it in 1 quarter.
Ergoteles's vTv Therapeutics position peaked at $124K in Q2 2021.
31 funds tracked by Wall St. Rank held vTv Therapeutics as of Q3 2021.

Based on Ergoteles's 13F filing for Q3 2021, filed 15 Nov 2021.